Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation Indian Medical PG Practice Questions and MCQs

Question 251: Low molecular weight heparin acts on which coagulation factor?

A. Factor XIa
B. Factor Xa (Correct Answer)
C. Factor IXa
D. Factor IIa

Explanation: **Explanation:** Low Molecular Weight Heparins (LMWHs), such as Enoxaparin and Dalteparin, are derived from the fractionation of Unfractionated Heparin (UFH). Their mechanism of action involves binding to **Antithrombin III (AT-III)**, inducing a conformational change that accelerates the inactivation of coagulation factors. The key distinction lies in the molecular chain length. To inactivate **Factor Xa**, only the pentasaccharide sequence of heparin is required to bind to AT-III. However, to inactivate **Thrombin (Factor IIa)**, the heparin chain must be long enough (at least 18 saccharide units) to bridge AT-III and Thrombin together. LMWH chains are shorter; therefore, they efficiently catalyze the inhibition of Factor Xa but have significantly less effect on Factor IIa (ratio of Xa:IIa activity is typically 3:1 or 4:1). **Analysis of Options:** * **Option B (Correct):** LMWH primarily inhibits Factor Xa due to its specific molecular structure. * **Option D (Incorrect):** While Unfractionated Heparin (UFH) inhibits both IIa and Xa equally (1:1 ratio), LMWH has minimal activity against Factor IIa. * **Options A & C (Incorrect):** Factors XIa and IXa are inhibited by the Heparin-AT-III complex to a much lesser extent and are not the primary targets for LMWH. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** Unlike UFH, LMWH does not require routine aPTT monitoring due to a predictable dose-response. If monitoring is needed (e.g., in renal failure or pregnancy), **Anti-Factor Xa levels** are measured. * **Elimination:** LMWH is primarily excreted **renally**; thus, it is contraindicated or requires dose adjustment in chronic kidney disease (UFH is preferred here). * **Antidote:** Protamine sulfate only partially reverses LMWH (approx. 60-75%), whereas it fully reverses UFH. * **Advantage:** LMWH has a lower risk of Heparin-Induced Thrombocytopenia (HIT) and osteoporosis compared to UFH.

Question 252: Which of the following prevents plasminogen activators?

A. Streptokinase
B. Aminocaproic acid (Correct Answer)
C. Reteplase
D. Clopidogrel

Explanation: ### Explanation The correct answer is **Aminocaproic acid**. **Mechanism of Action:** Aminocaproic acid (and its more potent analog, Tranexamic acid) is an **antifibrinolytic agent**. It acts as a lysine analog that binds to the lysine-binding sites on **plasminogen and plasmin**. By doing so, it competitively inhibits the binding of plasminogen to fibrin and prevents its conversion into active plasmin by plasminogen activators (like tPA or urokinase). Ultimately, it inhibits fibrinolysis and stabilizes clots. **Analysis of Incorrect Options:** * **A. Streptokinase:** This is a **fibrinolytic (thrombolytic)** agent. It is a protein derived from streptococci that binds with plasminogen to form an active complex, which then converts free plasminogen into plasmin to dissolve clots. * **C. Reteplase:** This is a recombinant **tissue plasminogen activator (tPA)**. Like Alteplase and Tenecteplase, it directly activates plasminogen to promote clot lysis. It is used in the management of acute myocardial infarction. * **D. Clopidogrel:** This is an **antiplatelet drug**. It works by irreversibly blocking the **P2Y12 receptor** for ADP on the platelet surface, preventing platelet aggregation. It has no direct effect on the plasminogen system. **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Uses:** Aminocaproic acid is used to treat bleeding associated with hyperfibrinolysis, such as post-prostatectomy bleeding, tooth extraction in hemophiliacs, or thrombolytic overdose. * **Tranexamic Acid (TXA):** It is 7–10 times more potent than aminocaproic acid and is the preferred agent in trauma and heavy menstrual bleeding (menorrhagia). * **Side Effects:** A significant risk of antifibrinolytics is the potential for **thrombosis** (DVT/PE) and, specifically for aminocaproic acid, **myopathy/rhabdomyolysis**.

Question 253: Heparin does not cause which of the following?

A. Osteoporosis
B. Factor V inhibition (Correct Answer)
C. Thrombocytopenia
D. Prolongation of aPTT

Explanation: ### Explanation **Correct Answer: B. Factor V inhibition** **Mechanism of Action:** Heparin acts by binding to **Antithrombin III (AT-III)**, which induces a conformational change that accelerates the inactivation of various clotting factors. Heparin primarily inhibits **Thrombin (Factor IIa)** and **Factor Xa**. It also inhibits Factors IXa, XIa, and XIIa. **Factor V** is a cofactor, not a serine protease; therefore, it is **not** directly inhibited by the Heparin-AT III complex. **Analysis of Incorrect Options:** * **A. Osteoporosis:** Long-term heparin therapy (usually >3–6 months) can lead to decreased bone density and osteoporosis. This occurs because heparin stimulates osteoclasts and inhibits osteoblast activity. * **C. Thrombocytopenia:** Heparin-Induced Thrombocytopenia (HIT) is a significant side effect. Type II HIT is an immune-mediated reaction where antibodies form against the Heparin-Platelet Factor 4 (PF4) complex, leading to paradoxically increased thrombosis and low platelet counts. * **D. Prolongation of aPTT:** The activated Partial Thromboplastin Time (aPTT) measures the intrinsic and common pathways. Since heparin inhibits Factors II, IX, X, XI, and XII, it significantly prolongs aPTT, which is the standard test for monitoring Unfractionated Heparin (UFH). **High-Yield Clinical Pearls for NEET-PG:** * **Antidote:** Protamine sulfate (a basic protein that neutralizes acidic heparin). * **LMWH vs. UFH:** Low Molecular Weight Heparin (e.g., Enoxaparin) mainly inhibits Factor Xa and has a lower risk of HIT and osteoporosis compared to UFH. * **Monitoring:** UFH is monitored by **aPTT**, while LMWH monitoring (if required) is done via **Anti-Xa levels**. * **Safe in Pregnancy:** Heparin does not cross the placenta, making it the anticoagulant of choice during pregnancy.

Question 254: Lepirudin is used in:

A. Heparin overdose
B. Warfarin overdose
C. Heparin induced thrombocytopenia (Correct Answer)
D. Warfarin induced dermal vascular necrosis

Explanation: **Lepirudin** is a recombinant derivative of hirudin (originally found in medicinal leeches) and belongs to the class of **Direct Thrombin Inhibitors (DTIs)** [1]. Unlike heparin, it does not require Antithrombin III as a cofactor and can directly inhibit both circulating and clot-bound thrombin. **Why Option C is correct:** **Heparin-Induced Thrombocytopenia (HIT)** is a prothrombotic immune-mediated reaction caused by antibodies against the Heparin-Platelet Factor 4 complex [2]. In patients with HIT, all heparin products must be discontinued immediately. Lepirudin (along with Argatroban and Bivalirudin) is used as an alternative anticoagulant because it provides effective anticoagulation without cross-reacting with HIT antibodies [2]. **Why other options are incorrect:** * **Option A (Heparin overdose):** The specific antidote for heparin overdose is **Protamine sulfate** [1]. Lepirudin would worsen the bleeding. * **Option B (Warfarin overdose):** Management involves **Vitamin K** (slow reversal) or **Prothrombin Complex Concentrate (PCC)/Fresh Frozen Plasma (FFP)** for immediate reversal. * **Option D (Warfarin induced dermal vascular necrosis):** This occurs due to a rapid decline in Protein C levels. Treatment involves stopping Warfarin and administering **Vitamin K and Heparin** (or DTIs if HIT is suspected) to provide anticoagulation while Protein C levels recover. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** The efficacy of Lepirudin is monitored using **aPTT** (Activated Partial Thromboplastin Time) [1]. * **Excretion:** Lepirudin is primarily **renally excreted** [1]; dose adjustment is critical in renal failure (Argatroban is the DTI of choice in renal failure as it is hepatically cleared). * **Antidote:** There is **no specific antidote** for Lepirudin [1]. * **Other DTIs:** Bivalirudin (used in PCI), Argatroban (small molecule DTI), and Dabigatran (oral DTI).

Question 255: What is true about iron?

A. Parenteral iron is indicated when anemia responds slowly to oral iron.
B. Ferrous sulfate 200mg has less elemental iron than the same dose of ferrous gluconate.
C. Sustained-release iron is a useful way of giving larger doses.
D. Absorption of iron is increased by ascorbic acid. (Correct Answer)

Explanation: **Explanation:** **1. Why Option D is Correct:** Iron absorption occurs primarily in the duodenum and upper jejunum. Dietary iron exists in two forms: Heme and Non-heme (ferric, $Fe^{3+}$). For non-heme iron to be absorbed, it must be in the **ferrous ($Fe^{2+}$) state**. **Ascorbic acid (Vitamin C)** acts as a reducing agent that converts ferric iron to ferrous iron and forms a soluble chelate, significantly enhancing its absorption. Conversely, phosphates, phytates, and tea (tannins) inhibit absorption. **2. Why Other Options are Incorrect:** * **Option A:** Parenteral iron is **not** indicated for a "slow response." The rate of hemoglobin rise is generally the same for both oral and parenteral routes. Indications for parenteral iron include oral intolerance, malabsorption (e.g., Celiac disease), or when rapid replenishment of stores is needed (e.g., late pregnancy). * **Option B:** Ferrous sulfate contains **20%** elemental iron (200mg $\approx$ 60mg iron), whereas Ferrous gluconate contains only **12%** (200mg $\approx$ 24mg iron). Thus, sulfate has *more* elemental iron. * **Option C:** Sustained-release (SR) formulations are generally **discouraged**. Iron is best absorbed in the duodenum; SR preparations often bypass this "absorption window," releasing iron in the distal small intestine where absorption is poor. **High-Yield Clinical Pearls for NEET-PG:** * **Oral Iron:** Best taken on an empty stomach for maximum absorption, though often taken with food to reduce GI side effects (gastritis, metallic taste). * **Parenteral Iron:** Iron Dextran carries a risk of **anaphylaxis** (requires a test dose). Iron Sucrose and Ferric Carboxymaltose are safer alternatives. * **Toxicity:** Acute iron poisoning is treated with **Deferoxamine** (IV). Chronic iron overload (hemosiderosis) is treated with **Deferiprone** or **Deferasirox** (Oral).

Question 256: Which clotting factor level falls first after administering warfarin?

A. Factor V
B. Factor VI
C. Factor VII (Correct Answer)
D. Factor VIII

Explanation: **Explanation:** Warfarin acts as a Vitamin K antagonist by inhibiting the enzyme **Vitamin K Epoxide Reductase (VKOR)**. This prevents the gamma-carboxylation of glutamate residues on Vitamin K-dependent clotting factors: **II, VII, IX, and X**, as well as endogenous anticoagulants **Protein C and S**. The speed at which these factors decline depends entirely on their individual **plasma half-lives**. 1. **Factor VII** has the shortest half-life (approximately **4–6 hours**). Therefore, it is the first clotting factor to be depleted, leading to an initial rise in the Prothrombin Time (PT/INR). 2. **Factor IX** (approx. 24 hours), **Factor X** (approx. 48 hours), and **Factor II** (approx. 60–72 hours) follow sequentially. **Analysis of Incorrect Options:** * **Factor V & VIII:** These are not Vitamin K-dependent factors. Their synthesis is unaffected by warfarin therapy. * **Factor VI:** This is an obsolete term; Factor VI is actually activated Factor V (Va) and is not a distinct Vitamin K-dependent factor. **High-Yield Clinical Pearls for NEET-PG:** * **The "Procoagulant Phase":** Protein C has a very short half-life (~6 hours), similar to Factor VII. Its early depletion can create a transient hypercoagulable state, which is why **heparin bridging** is required when starting warfarin to prevent **Warfarin-induced Skin Necrosis**. * **Full Anticoagulant Effect:** While PT/INR rises early due to Factor VII depletion, the full antithrombotic effect is not achieved until **Factor II (Prothrombin)** is depleted, which takes 3–5 days. * **Monitoring:** Warfarin is monitored using **PT/INR** (Extrinsic pathway), while Heparin is monitored using **aPTT** (Intrinsic pathway).

Question 257: Which of the following is an oral thrombin inhibitor?

A. Rivaroxaban
B. Dabigatran (Correct Answer)
C. Argatroban
D. Alfimeprase

Explanation: **Explanation:** **Dabigatran** is the correct answer because it is a **Direct Thrombin Inhibitor (DTI)** that is administered **orally**. It works by binding directly to both free and clot-bound thrombin (Factor IIa), preventing the conversion of fibrinogen to fibrin. It is a prodrug (Dabigatran etexilate) and is commonly used for stroke prevention in non-valvular atrial fibrillation and the treatment of DVT/PE. **Analysis of Incorrect Options:** * **A. Rivaroxaban:** While oral, it is a **Direct Factor Xa inhibitor** (not a thrombin inhibitor). Remember: drugs with "-xaban" in the name "ban" Factor **Xa**. * **C. Argatroban:** This is a Direct Thrombin Inhibitor, but it is administered **intravenously**, not orally. It is primarily used in patients with Heparin-Induced Thrombocytopenia (HIT). * **D. Alfimeprase:** This is a recombinant truncated form of plasminogen activator (a **thrombolytic** agent), not an anticoagulant. **High-Yield Clinical Pearls for NEET-PG:** * **Reversal Agent:** The specific antidote for Dabigatran is **Idarucizumab** (a monoclonal antibody fragment). * **Monitoring:** Unlike Warfarin, Dabigatran does not require routine INR monitoring. However, at high doses, it can prolong the **aPTT** and **Thrombin Time (TT)**. * **Excretion:** It is primarily eliminated by the **kidneys**; therefore, dose adjustment or avoidance is necessary in chronic kidney disease. * **Comparison:** Other parenteral DTIs include Lepirudin and Bivalirudin (derived from leech saliva/hirudin).

Question 258: Which fibrinolytic agent selectively activates fibrin-bound plasminogen rather than circulating plasminogen?

A. Streptokinase
B. Urokinase
C. Alteplase (Correct Answer)
D. Both Streptokinase and Alteplase

Explanation: ### Explanation **Concept: Fibrin Selectivity** Fibrinolytic agents (thrombolytics) work by converting plasminogen into plasmin, which then degrades fibrin clots. These agents are classified based on their **fibrin selectivity**: 1. **Fibrin-Specific Agents (e.g., Alteplase):** These agents have a high affinity for plasminogen that is already bound to a fibrin clot. They cause "clot-guided" thrombolysis, meaning they primarily activate plasminogen at the site of the thrombus. This minimizes the systemic conversion of circulating plasminogen, theoretically reducing the risk of systemic bleeding. 2. **Non-Specific Agents (e.g., Streptokinase):** These activate both fibrin-bound and circulating (free) plasminogen indiscriminately. This leads to a "systemic lytic state" characterized by the depletion of circulating fibrinogen and clotting factors (V and VIII). **Analysis of Options:** * **Alteplase (Correct):** It is a recombinant Tissue Plasminogen Activator (rt-PA). It is highly fibrin-selective, making it the preferred agent in acute ischemic stroke and MI. * **Streptokinase (Incorrect):** Derived from Beta-hemolytic Streptococci, it is non-specific and antigenic. It can cause systemic fibrinogenolysis and allergic reactions. * **Urokinase (Incorrect):** An enzyme naturally produced by the kidneys; it directly activates plasminogen but lacks fibrin selectivity. **High-Yield NEET-PG Pearls:** * **Tenecteplase:** The most fibrin-selective agent with the longest half-life, allowing for a single bolus dose. * **Reteplase:** Another rt-PA, but less fibrin-selective than Alteplase. * **Antidote:** In case of overdose or excessive bleeding, **Epsilon-aminocaproic acid (EACA)** or **Tranexamic acid** are used as fibrinolytic inhibitors. * **Contraindication:** History of hemorrhagic stroke is an absolute contraindication for all fibrinolytics.

Question 259: Heparin is the most widely used antithrombotic agent. It acts by activating which of the following?

A. Plasmin
B. Antithrombin III (Correct Answer)
C. Fibrinolysin
D. Factor X

Explanation: ### Explanation **Correct Option: B. Antithrombin III** Heparin is an indirect-acting anticoagulant. It works by binding to **Antithrombin III (AT-III)**, a natural plasma protease inhibitor. This binding induces a conformational change in AT-III, accelerating its activity by nearly 1,000-fold. The Heparin-AT-III complex then inactivates several clotting factors, primarily **Thrombin (Factor IIa)** and **Factor Xa**, as well as factors IXa, XIa, and XIIa. * **Unfractionated Heparin (UFH):** Inactivates both IIa and Xa. * **Low Molecular Weight Heparin (LMWH):** Primarily inactivates Factor Xa. --- ### Why Other Options are Incorrect: * **A & C (Plasmin/Fibrinolysin):** These are synonymous. Plasmin is the active enzyme responsible for **fibrinolysis** (breaking down an existing clot). Drugs that activate plasminogen to plasmin are called Thrombolytics (e.g., Streptokinase, Alteplase), not anticoagulants like Heparin. * **D (Factor X):** Heparin does not *activate* Factor X; it leads to its **inhibition**. Direct Factor Xa inhibitors (e.g., Rivaroxaban, Apixaban) act directly on this factor without requiring AT-III. --- ### High-Yield NEET-PG Pearls: 1. **Monitoring:** UFH is monitored using **aPTT** (intrinsic pathway). LMWH usually does not require monitoring but can be checked using **Anti-Xa levels**. 2. **Antidote:** The specific antagonist for Heparin overdose is **Protamine Sulfate** (a strongly basic protein that neutralizes acidic heparin). 3. **Side Effect:** A critical immune-mediated complication is **Heparin-Induced Thrombocytopenia (HIT)**, caused by antibodies against the Heparin-Platelet Factor 4 (PF4) complex. 4. **Safe in Pregnancy:** Heparin does not cross the placenta, making it the anticoagulant of choice during pregnancy.

Question 260: Which of the following is an antidote for heparin?

A. Sodium nitrite
B. Protamine sulfate (Correct Answer)
C. Thiosulfate
D. Coumarin

Explanation: **Explanation:** **Correct Option: B. Protamine sulfate** Heparin is a highly acidic, negatively charged molecule (polysaccharide). **Protamine sulfate** is a low-molecular-weight, strongly basic, positively charged protein derived from salmon sperm. When administered, it reacts with heparin through an **ionic interaction** to form a stable, inactive salt (neutralization complex). This is a classic example of **chemical antagonism**. * *Dosing:* 1 mg of protamine sulfate neutralizes approximately 100 units of heparin. * *Note:* It is more effective against Unfractionated Heparin (UFH) than Low Molecular Weight Heparin (LMWH). **Incorrect Options:** * **A & C (Sodium nitrite & Thiosulfate):** These are components of the treatment regimen for **Cyanide poisoning**. Sodium nitrite induces methemoglobinemia to bind cyanide, while thiosulfate acts as a sulfur donor to convert cyanide into non-toxic thiocyanate. * **D (Coumarin):** This is a class of oral anticoagulants (e.g., Warfarin) that acts as a Vitamin K antagonist. It is not an antidote; rather, its own effects are reversed by Vitamin K or Fresh Frozen Plasma (FFP). **High-Yield Clinical Pearls for NEET-PG:** 1. **Protamine Paradox:** In high doses, protamine itself has a weak anticoagulant effect (it inhibits platelets and interacts with fibrinogen). 2. **Adverse Effects:** Rapid IV injection of protamine can cause **histamine release**, leading to hypotension, bradycardia, and pulmonary hypertension. 3. **Monitoring:** The efficacy of heparin is monitored by **aPTT**, while its reversal by protamine is monitored by **ACT** (Activated Clotting Time) during cardiac surgeries.

Practice by Chapter

Hematopoietic Growth Factors

Practice Questions

Iron Preparations and Management of Iron Deficiency

Practice Questions

Vitamin B12 and Folic Acid

Practice Questions

Anticoagulants: Heparins and Direct Inhibitors

Practice Questions

Oral Anticoagulants

Practice Questions

Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Hemostatic Drugs

Practice Questions

Plasma Expanders

Practice Questions

Blood Transfusion and Alternatives

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free